JP2009520825A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009520825A5 JP2009520825A5 JP2008547525A JP2008547525A JP2009520825A5 JP 2009520825 A5 JP2009520825 A5 JP 2009520825A5 JP 2008547525 A JP2008547525 A JP 2008547525A JP 2008547525 A JP2008547525 A JP 2008547525A JP 2009520825 A5 JP2009520825 A5 JP 2009520825A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hetero
- indazol
- thiazol
- bicycloaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000000217 alkyl group Chemical group 0.000 claims 132
- 125000005842 heteroatom Chemical group 0.000 claims 59
- -1 cyano, thio, oxy, hydroxy, carbonyloxy Chemical group 0.000 claims 54
- 150000001875 compounds Chemical class 0.000 claims 51
- 125000000753 cycloalkyl group Chemical group 0.000 claims 35
- 229910052739 hydrogen Inorganic materials 0.000 claims 27
- 239000001257 hydrogen Substances 0.000 claims 27
- 125000003545 alkoxy group Chemical group 0.000 claims 25
- 125000003118 aryl group Chemical group 0.000 claims 25
- 125000001475 halogen functional group Chemical group 0.000 claims 23
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 18
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 18
- 150000001602 bicycloalkyls Chemical group 0.000 claims 17
- 150000002431 hydrogen Chemical class 0.000 claims 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 14
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 125000003282 alkyl amino group Chemical group 0.000 claims 11
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims 11
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 10
- 125000004104 aryloxy group Chemical group 0.000 claims 9
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 9
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 9
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 229940124530 sulfonamide Drugs 0.000 claims 4
- 150000003456 sulfonamides Chemical class 0.000 claims 4
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 3
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims 3
- VRVVEIMGCXAUFX-UHFFFAOYSA-N 1-[3-(1,3-thiazol-2-ylamino)-1h-indazol-5-yl]ethanone Chemical compound C12=CC(C(=O)C)=CC=C2NN=C1NC1=NC=CS1 VRVVEIMGCXAUFX-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- ZGUYXJMAUSIGGJ-UHFFFAOYSA-N n-(5-bromo-1h-indazol-3-yl)-1,3-thiazol-2-amine Chemical compound C12=CC(Br)=CC=C2NN=C1NC1=NC=CS1 ZGUYXJMAUSIGGJ-UHFFFAOYSA-N 0.000 claims 2
- DYOWAHFLBRMDPA-UHFFFAOYSA-N n-(5-nitro-1h-indazol-3-yl)-1,3-thiazol-2-amine Chemical compound C12=CC([N+](=O)[O-])=CC=C2NN=C1NC1=NC=CS1 DYOWAHFLBRMDPA-UHFFFAOYSA-N 0.000 claims 2
- OSLQGBPFPHAKMB-UHFFFAOYSA-N n-(5-propan-2-yl-1h-indazol-3-yl)-1,3-thiazol-2-amine Chemical compound C12=CC(C(C)C)=CC=C2NN=C1NC1=NC=CS1 OSLQGBPFPHAKMB-UHFFFAOYSA-N 0.000 claims 2
- PIPLDRSEUYWYBS-UHFFFAOYSA-N n-(5-propan-2-yloxy-1h-indazol-3-yl)-1,3-thiazol-2-amine Chemical compound C12=CC(OC(C)C)=CC=C2NN=C1NC1=NC=CS1 PIPLDRSEUYWYBS-UHFFFAOYSA-N 0.000 claims 2
- IPCNZDZFRSNTOW-UHFFFAOYSA-N n-[1-methyl-5-(trifluoromethyl)indazol-3-yl]-1,3-thiazol-2-amine Chemical compound C12=CC(C(F)(F)F)=CC=C2N(C)N=C1NC1=NC=CS1 IPCNZDZFRSNTOW-UHFFFAOYSA-N 0.000 claims 2
- LEHPHLIERWUZBJ-UHFFFAOYSA-N n-[3-(1,3-thiazol-2-ylamino)-1h-indazol-5-yl]acetamide Chemical compound C12=CC(NC(=O)C)=CC=C2NN=C1NC1=NC=CS1 LEHPHLIERWUZBJ-UHFFFAOYSA-N 0.000 claims 2
- FKZNSRSKGSEYDB-UHFFFAOYSA-N n-[5-(2-methylpropyl)-1h-indazol-3-yl]-1,3-thiazol-2-amine Chemical compound C12=CC(CC(C)C)=CC=C2NN=C1NC1=NC=CS1 FKZNSRSKGSEYDB-UHFFFAOYSA-N 0.000 claims 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 2
- RKGTUWFVQBAKSG-UHFFFAOYSA-N 3-(1,3-thiazol-2-ylamino)-1h-indazol-5-ol Chemical compound C12=CC(O)=CC=C2NN=C1NC1=NC=CS1 RKGTUWFVQBAKSG-UHFFFAOYSA-N 0.000 claims 1
- KSJHXQGNWAXPLD-UHFFFAOYSA-N 3-n-(1,3-thiazol-2-yl)-1h-indazole-3,5-diamine Chemical compound C12=CC(N)=CC=C2NN=C1NC1=NC=CS1 KSJHXQGNWAXPLD-UHFFFAOYSA-N 0.000 claims 1
- XSFRCCSMVPAZKQ-UHFFFAOYSA-N 4-methyl-n-[5-(trifluoromethyl)-1h-indazol-3-yl]-1,3-thiazol-2-amine Chemical compound CC1=CSC(NC=2C3=CC(=CC=C3NN=2)C(F)(F)F)=N1 XSFRCCSMVPAZKQ-UHFFFAOYSA-N 0.000 claims 1
- SJLFPYGIIODEOP-UHFFFAOYSA-N 4-phenyl-n-[5-(trifluoromethyl)-1h-indazol-3-yl]-1,3-thiazol-2-amine Chemical compound C12=CC(C(F)(F)F)=CC=C2NN=C1NC(SC=1)=NC=1C1=CC=CC=C1 SJLFPYGIIODEOP-UHFFFAOYSA-N 0.000 claims 1
- YSDSPSWPPIPXQE-UHFFFAOYSA-N 4-phenyl-n-[6-(trifluoromethyl)-1h-indazol-3-yl]-1,3-thiazol-2-amine Chemical compound N=1NC2=CC(C(F)(F)F)=CC=C2C=1NC(SC=1)=NC=1C1=CC=CC=C1 YSDSPSWPPIPXQE-UHFFFAOYSA-N 0.000 claims 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 1
- DWLGPAFJARLTLU-UHFFFAOYSA-N [3-(1,3-thiazol-2-ylamino)-1h-indazol-5-yl]methanol Chemical compound C12=CC(CO)=CC=C2NN=C1NC1=NC=CS1 DWLGPAFJARLTLU-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- FYKPUSGJVYSSEP-UHFFFAOYSA-N ethyl 2-[[5-(trifluoromethyl)-1h-indazol-3-yl]amino]-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC(NC=2C3=CC(=CC=C3NN=2)C(F)(F)F)=N1 FYKPUSGJVYSSEP-UHFFFAOYSA-N 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- MWZXNXHUVRZKHT-UHFFFAOYSA-N n-(4,5-dimethyl-1h-indazol-3-yl)-1,3-thiazol-2-amine Chemical compound C12=C(C)C(C)=CC=C2NN=C1NC1=NC=CS1 MWZXNXHUVRZKHT-UHFFFAOYSA-N 0.000 claims 1
- ABYYJDIMKIVCOK-UHFFFAOYSA-N n-(5-chloro-1h-indazol-3-yl)-1,3-thiazol-2-amine Chemical compound C12=CC(Cl)=CC=C2NN=C1NC1=NC=CS1 ABYYJDIMKIVCOK-UHFFFAOYSA-N 0.000 claims 1
- CYWATKQBFOCIKN-UHFFFAOYSA-N n-(5-ethyl-1h-indazol-3-yl)-1,3-thiazol-2-amine Chemical compound C12=CC(CC)=CC=C2NN=C1NC1=NC=CS1 CYWATKQBFOCIKN-UHFFFAOYSA-N 0.000 claims 1
- ATGNXJRDHVZKSR-UHFFFAOYSA-N n-(5-methoxy-1h-indazol-3-yl)-1,3-thiazol-2-amine Chemical compound C12=CC(OC)=CC=C2NN=C1NC1=NC=CS1 ATGNXJRDHVZKSR-UHFFFAOYSA-N 0.000 claims 1
- BPZFHQSYMJYRLF-UHFFFAOYSA-N n-(5-propyl-1h-indazol-3-yl)-1,3-thiazol-2-amine Chemical compound C12=CC(CCC)=CC=C2NN=C1NC1=NC=CS1 BPZFHQSYMJYRLF-UHFFFAOYSA-N 0.000 claims 1
- UDSQJLGHYXAXOM-UHFFFAOYSA-N n-(7-bromo-5-propyl-1h-indazol-3-yl)-1,3-thiazol-2-amine Chemical compound C12=CC(CCC)=CC(Br)=C2NN=C1NC1=NC=CS1 UDSQJLGHYXAXOM-UHFFFAOYSA-N 0.000 claims 1
- LNVPFJINCZBXDL-UHFFFAOYSA-N n-(7-fluoro-1h-indazol-3-yl)-1,3-thiazol-2-amine Chemical compound N=1NC=2C(F)=CC=CC=2C=1NC1=NC=CS1 LNVPFJINCZBXDL-UHFFFAOYSA-N 0.000 claims 1
- DLMKNUIWTBOKAR-UHFFFAOYSA-N n-[1-(2-methylpropyl)-5-(trifluoromethyl)indazol-3-yl]-1,3-thiazol-2-amine Chemical compound C12=CC(C(F)(F)F)=CC=C2N(CC(C)C)N=C1NC1=NC=CS1 DLMKNUIWTBOKAR-UHFFFAOYSA-N 0.000 claims 1
- ZBYUFWGBSLXVSZ-UHFFFAOYSA-N n-[1-(3-aminopropyl)-5-(trifluoromethyl)indazol-3-yl]-1,3-thiazol-2-amine Chemical compound C12=CC(C(F)(F)F)=CC=C2N(CCCN)N=C1NC1=NC=CS1 ZBYUFWGBSLXVSZ-UHFFFAOYSA-N 0.000 claims 1
- YEKDKCHBLYXRHR-UHFFFAOYSA-N n-[1-(4-aminobutyl)-5-(trifluoromethyl)indazol-3-yl]-1,3-thiazol-2-amine Chemical compound C12=CC(C(F)(F)F)=CC=C2N(CCCCN)N=C1NC1=NC=CS1 YEKDKCHBLYXRHR-UHFFFAOYSA-N 0.000 claims 1
- OODJJRXYMRKHKM-UHFFFAOYSA-N n-[1-[3-(dimethylamino)propyl]-5-(trifluoromethyl)indazol-3-yl]-1,3-thiazol-2-amine Chemical compound C12=CC(C(F)(F)F)=CC=C2N(CCCN(C)C)N=C1NC1=NC=CS1 OODJJRXYMRKHKM-UHFFFAOYSA-N 0.000 claims 1
- LLIZIGZUBNIWGD-UHFFFAOYSA-N n-[1-[4-(dimethylamino)butyl]-5-(trifluoromethyl)indazol-3-yl]-1,3-thiazol-2-amine Chemical compound C12=CC(C(F)(F)F)=CC=C2N(CCCCN(C)C)N=C1NC1=NC=CS1 LLIZIGZUBNIWGD-UHFFFAOYSA-N 0.000 claims 1
- LYANPFVDFMFUBR-UHFFFAOYSA-N n-[1-benzyl-5-(trifluoromethyl)indazol-3-yl]-1,3-thiazol-2-amine Chemical compound N1=C(NC=2SC=CN=2)C2=CC(C(F)(F)F)=CC=C2N1CC1=CC=CC=C1 LYANPFVDFMFUBR-UHFFFAOYSA-N 0.000 claims 1
- JPUVOLHNKNMYRD-UHFFFAOYSA-N n-[1-ethyl-5-(trifluoromethyl)indazol-3-yl]-1,3-thiazol-2-amine Chemical compound C12=CC(C(F)(F)F)=CC=C2N(CC)N=C1NC1=NC=CS1 JPUVOLHNKNMYRD-UHFFFAOYSA-N 0.000 claims 1
- DVRHCRNVBAYPFF-UHFFFAOYSA-N n-[4-(trifluoromethyl)-1h-indazol-3-yl]-1,3-thiazol-2-amine Chemical compound C1=2C(C(F)(F)F)=CC=CC=2NN=C1NC1=NC=CS1 DVRHCRNVBAYPFF-UHFFFAOYSA-N 0.000 claims 1
- YWRITFSHUTUVOB-UHFFFAOYSA-N n-[5-(1-methoxypropan-2-yloxy)-1h-indazol-3-yl]-1,3-thiazol-2-amine Chemical compound C12=CC(OC(C)COC)=CC=C2NN=C1NC1=NC=CS1 YWRITFSHUTUVOB-UHFFFAOYSA-N 0.000 claims 1
- PKRLEXSNYBLEAU-UHFFFAOYSA-N n-[5-(trifluoromethyl)-1h-indazol-3-yl]-1,3-thiazol-2-amine Chemical compound C12=CC(C(F)(F)F)=CC=C2NN=C1NC1=NC=CS1 PKRLEXSNYBLEAU-UHFFFAOYSA-N 0.000 claims 1
- MKSWHHUHYIMEEC-UHFFFAOYSA-N n-[7-(trifluoromethyl)-1h-indazol-3-yl]-1,3-thiazol-2-amine Chemical compound N=1NC=2C(C(F)(F)F)=CC=CC=2C=1NC1=NC=CS1 MKSWHHUHYIMEEC-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910017464 nitrogen compound Inorganic materials 0.000 claims 1
- 150000002830 nitrogen compounds Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 0 Cc1c(*)c(*)c(*N=C2N(C)c3nc(*)c(*)[s]3)c2c1* Chemical compound Cc1c(*)c(*)c(*N=C2N(C)c3nc(*)c(*)[s]3)c2c1* 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75275005P | 2005-12-20 | 2005-12-20 | |
| PCT/US2006/048714 WO2007075847A2 (en) | 2005-12-20 | 2006-12-19 | Glucokinase activators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009520825A JP2009520825A (ja) | 2009-05-28 |
| JP2009520825A5 true JP2009520825A5 (enExample) | 2009-12-17 |
Family
ID=38051016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008547525A Abandoned JP2009520825A (ja) | 2005-12-20 | 2006-12-19 | グルコキナーゼ活性剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070244169A1 (enExample) |
| EP (1) | EP1966152A2 (enExample) |
| JP (1) | JP2009520825A (enExample) |
| CA (1) | CA2633584A1 (enExample) |
| WO (1) | WO2007075847A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| WO2008156757A1 (en) * | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Indazole compounds for activating glucokinase |
| WO2009012312A1 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20100311072A1 (en) * | 2008-01-28 | 2010-12-09 | Bristol-Myers Squibb Company | Fluorescence polarization binding assay for characterizing glucokinase ligands |
| US8349886B2 (en) | 2008-04-16 | 2013-01-08 | Takeda Pharmaceutical Company Limited | Nitrogenated 5-membered heterocyclic compound |
| TWI445707B (zh) | 2008-05-16 | 2014-07-21 | Takeda California Inc | 葡萄糖激酶活化劑 |
| DE102009004245A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
| CN106692144A (zh) | 2009-03-11 | 2017-05-24 | 奥默罗斯公司 | 预防和治疗成瘾的组合物和方法 |
| CA2779088A1 (en) | 2009-11-16 | 2011-05-19 | Mellitech | [1,5]-diazocin derivatives |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| JP5909482B2 (ja) | 2010-03-31 | 2016-04-26 | ザ スクリプス リサーチ インスティテュート | 細胞の再プログラム |
| EP2569301A1 (en) | 2010-05-12 | 2013-03-20 | Abbvie Inc. | Indazole inhibitors of kinase |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| BR112015002295B1 (pt) | 2012-07-31 | 2022-02-01 | The Board Of Regents Of The University Of Texas System | Método para induzir a formação de célula beta in vitro |
| CA2940144C (en) * | 2014-02-20 | 2023-06-13 | Cornell University | Substituted indazol-3-yl derivatives and pharmaceutical compositions thereof useful as inhibitor of fascin |
| TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ｒｏｓ１突變癌細胞之分子 |
| CN107207471B (zh) | 2014-12-02 | 2020-06-26 | 伊尼塔公司 | 用于治疗神经母细胞瘤的组合 |
| US10221172B2 (en) | 2015-01-13 | 2019-03-05 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| JP7061068B2 (ja) | 2015-12-18 | 2022-04-27 | イグナイタ インコーポレイテッド | 癌治療のための併用薬 |
| CN121401264A (zh) | 2017-07-19 | 2026-01-27 | 伊尼塔公司 | 包括恩曲替尼的药物组合物 |
| WO2019077506A1 (en) | 2017-10-17 | 2019-04-25 | Ignyta, Inc. | PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS |
| CN110117278B (zh) * | 2018-02-07 | 2022-07-19 | 石家庄以岭药业股份有限公司 | 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途 |
| CN110015975A (zh) * | 2019-05-14 | 2019-07-16 | 浙江长华科技股份有限公司 | 一种2-氯-5-硝基苯甲腈微反应合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2653005A1 (de) * | 1975-12-03 | 1977-06-08 | Sandoz Ag | Neue organische verbindungen, ihre verwendung und herstellung |
| DK1318997T3 (da) * | 2000-09-15 | 2006-09-25 | Vertex Pharma | Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer |
| US6593349B2 (en) * | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| SE0102299D0 (sv) * | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| WO2004022544A1 (fr) * | 2002-09-05 | 2004-03-18 | Aventis Pharma S.A. | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant |
| MXPA05005554A (es) * | 2002-12-12 | 2005-07-26 | Aventis Pharma Sa | Derivados de aminoindazol y su utilizacion como inhibidores de quinasas. |
| EP1532980A1 (en) * | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
-
2006
- 2006-12-19 JP JP2008547525A patent/JP2009520825A/ja not_active Abandoned
- 2006-12-19 EP EP06845932A patent/EP1966152A2/en not_active Withdrawn
- 2006-12-19 US US11/613,059 patent/US20070244169A1/en not_active Abandoned
- 2006-12-19 WO PCT/US2006/048714 patent/WO2007075847A2/en not_active Ceased
- 2006-12-19 CA CA002633584A patent/CA2633584A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009520825A5 (enExample) | ||
| RU2461551C2 (ru) | Азолкарбоксамидное соединение или его фармацевтически приемлемая соль | |
| JP2009529059A5 (enExample) | ||
| JP2013530240A5 (enExample) | ||
| CA2553705A1 (en) | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them | |
| JP2010519181A5 (enExample) | ||
| CA2409697A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| JP2006077019A5 (enExample) | ||
| IL185759A0 (en) | Pharmaceutical preparation of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide | |
| JP2004517080A5 (enExample) | ||
| JP2010506825A5 (enExample) | ||
| RU2008117170A (ru) | Пиримидинамидные соединения как ингибиторы pgds | |
| JP2003534336A5 (enExample) | ||
| WO2012048181A4 (en) | Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors | |
| JP2010540462A5 (enExample) | ||
| JP2009524677A5 (enExample) | ||
| JP2006506439A5 (enExample) | ||
| JP2004521095A5 (enExample) | ||
| JP2009532379A5 (enExample) | ||
| JP2009513563A5 (enExample) | ||
| RU2006101053A (ru) | Производные бензамида или соль указанного производного | |
| JP2004504301A5 (enExample) | ||
| ZA200403137B (en) | Dibenzylamine compound and medicinal use thereof | |
| JP2013517273A5 (enExample) | ||
| HRP20160450T1 (hr) | Novi inhibitori reduktaze s-nitrozoglutationa |